People affected by migraine reluctant to see their doctor and keep their condition private at work due to fear of judgement, says study. The survey, conducted by the European Migraine & Headache Alliance (EMHA), found that the impact of migraine stigma was at the centre of their daily lives February 7, 2024. A new survey […]
Stigma survey press release Read More »
Migraine & Stigma Survey 2023 In 2023, the EMHA conducted a comprehensive pan-European digital survey answered by 4.210 people across 17 countries. In order to examinate the origins of stigma surrounding migraine, its impact on patients, and their need for better understanding and support. The survey covers various topics such as patients’ ease in sharing
Migraine and mental health in women: Addressing the challenge On September 21st, the EMHA presented with Gamian Europe the results on their study Migraine and mental health in women: Addressing the challenge. This report seeks to highlight the comorbidity between women affected by severe migraine attacks and mental health conditions. Over 15% of the European
Migraine and mental health in women Read More »
The European Medicines Agency (EMA) is recommending new measures to prevent children’s exposure to topiramate-containing medicines during pregnancy due to an increased risk of neurodevelopmental problems. Topiramate, used for epilepsy and migraine treatment, has known birth defect risks when used during pregnancy. The recommendations include: The product information for topiramate-containing medicines will be updated to
Topiramate exposure in pregnancy: PRAC recommends new measures Read More »
Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies Online course Access the 4 module course on Migraine, dealing with topics including innovative treatments (Anti-CGRP), patient’s perspective and key updates on the field.
Anti-CGRP Migraine Read More »
EMHA’s participation at the EAN Congress and IHS roundtable. The EMHA actively participated in the IHS Business Roundtable held during the EAN Congress 2023 in Budapest. This collaborative event brought together science, industry, and patients, aiming to shape a brighter future for future generations. Additionally, on July 1st, Elena Ruiz de la Torre, representing the
Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: Research Subanesthetic ketamine infusion has been used for managing refractory headache in inpatient or outpatient infusion settings. Intranasal ketamine may be an alternative option for outpatient care. Methods A retrospective study was conducted at a single tertiary headache center to assess the clinical
Intranasal ketamine for chronic migraine Read More »
At EMHA, we believe that the health and wellbeing of employees is paramount to their success in the workplace. That’s why we were proud to co-host a conference with BBVA that centered on health and emotional management. Our esteemed guest, Professor Peter Goadsby from King’s College London, provided valuable insights on migraines and how to
EMHA and Prof. Peter Goadsby at BBVA. Read More »
My migraines are a super power By Harris A. Eyre MD PhD “You may encounter many defeats, but you must not be defeated. In fact, it may be necessary to encounter the defeats so you can know who you are, what you can rise from, and how you can still come out of it.” —
My migraines are a super power Read More »
Managing Migraine at work Is it possible to create a safe and inclusive workplace for managing Migraine at work?Yes, it is. Companies need to be aware that an environment that meets the specific needs of those suffering from invisible diseases can become a facilitator and that it is necessary to apply design criteria that reduce
Managing Migraine at work Read More »
Don't miss out on any updates! Join our community and discover
the latest research, treatments, and events on migraine.
Subscribe now!
